Ability of myeloma cells to secrete macrophage inflammatory protein (MIP)-1α and MIP-1β correlates with lytic bone lesions in patients with multiple myeloma

被引:67
作者
Hashimoto, T
Abe, M
Oshima, T
Shibata, H
Ozaki, S
Inoue, D
Matsumoto, T
机构
[1] Univ Tokushima, Grad Sch Med, Dept Med & Bioregulatory Sci, Tokushima 7708503, Japan
[2] Tokushima Univ Hosp, Div Transfus Med, Tokushima, Japan
关键词
multiple myeloma; chemokines; bone disease;
D O I
10.1111/j.1365-2141.2004.04864.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Macrophage inflammatory protein (MIP)-1alpha and MIP-1beta have been identified as candidates for multiple myeloma (MM)-derived bone-resorbing factors. To validate the clinical relevance of these observations, we investigated correlations between the ability of MM cells to secrete these chemokines and the extent of MM bone lesions as well as levels of biochemical bone markers in patients with MM. Patients with multiple bone lesions exhibited higher MIP-1alpha and MIP-1beta secretion from MM cells along with elevated urinary deoxypyridinoline (Dpd), without significant elevation of serum bone-specific alkaline phosphatase (BALP) or osteocalcin compared with those with minimal bone lesions. MIP-1alpha and MIP-1beta levels correlated positively with urinary Dpd and serum BALP but not with serum osteocalcin. These results provide further evidence for a causal role of MIP-1alpha and MIP-1beta in the development of lytic bone lesions, and suggest that MM cells suppress osteoblastic bone formation to cause an imbalance of bone turnover and development of destructive bone lesions.
引用
收藏
页码:38 / 41
页数:4
相关论文
共 13 条
[1]   Role for macrophage inflammatory protein (MIP)-1α and MIP-1β in the development of osteolytic lesions in multiple myeloma [J].
Abe, M ;
Hiura, K ;
Wilde, J ;
Moriyama, K ;
Hashimoto, T ;
Ozaki, S ;
Wakatsuki, S ;
Kosaka, M ;
Kido, S ;
Inoue, D ;
Matsumoto, T .
BLOOD, 2002, 100 (06) :2195-2202
[2]   Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeloma patients [J].
Alexandrakis, MG ;
Passam, FH ;
Malliaraki, N ;
Katachanakis, C ;
Kyriakou, DS ;
Margioris, AN .
CLINICA CHIMICA ACTA, 2002, 325 (1-2) :51-57
[3]  
BARILLE S, 1995, BLOOD, V86, P3151
[4]   Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease [J].
Choi, SJ ;
Oba, Y ;
Gazitt, Y ;
Alsina, M ;
Cruz, J ;
Anderson, J ;
Roodman, GD .
JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (12) :1833-1841
[5]  
Choi SJ, 2000, BLOOD, V96, P671
[6]  
GOTO T, 1994, BLOOD, V84, P1922
[7]   Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand [J].
Han, JH ;
Choi, SJ ;
Kurihara, N ;
Koide, M ;
Oba, Y ;
Roodman, GD .
BLOOD, 2001, 97 (11) :3349-3353
[8]  
Khosla S, 2003, PRIMER METABOLIC BON, P166
[9]   Immunotherapy of multiple myeloma with a monoclonal antibody directed against a plasma cell-specific antigen, HM1.24 [J].
Ozaki, S ;
Kosaka, M ;
Wakatsuki, S ;
Abe, M ;
Koishihara, Y ;
Matsumoto, T .
BLOOD, 1997, 90 (08) :3179-3186
[10]   Bone resorption in multiple myeloma and in monoclonal gammopathy of undetermined significance: Quantification by urinary pyridinium cross-links of collagen [J].
Pecherstorfer, M ;
Seibel, MJ ;
Woitge, HW ;
Horn, E ;
Schuster, J ;
Neuda, J ;
Sagaster, P ;
Kohn, H ;
Bayer, P ;
Thiebaud, D ;
Ludwig, H .
BLOOD, 1997, 90 (09) :3743-3750